MAPK3 and breast cancer: The inhibitors of PI3K-AKT and ERK1/2 pathways, LY294002 and U0126 significantly suppressed EMT, indicating that AKT and ERK1/2 pathways are required for miR-21 mediating EMT in breast cancer [27].